JonathanKayMD(He/Him)

PubMed

• American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022.
  Jonathan Kay, Nikolay P Nikolov, Michael H Weisman,
  Arthritis & Rheumatology. 2024-09-01
• Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis.
  Divya Shridharmurthy, Kate L Lapane, Jonggyu Baek, Anthony P Nunes, Michael H Weisman
  Arthritis Care & Research. 2024-08-01
• Axial spondyloarthritis guidelines - aiming for maximum impact.
  Mathieu Choufani, Jonathan Kay, Joerg Ermann
  Current Opinion in Rheumatology. 2024-07-01

Journal Articles

• Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin.  
  Hou FF, Boyce J, Chertow GM, Kay J, Owen WF Jr, J Am Soc Nephrol 1998;9:277-83
• Nephrogenic systemic fibrosis.  
  Bernstein EJ, Schmidt-Lauber C, Kay J, Best Pract Res Clin Rheumatol 10.1016/j.berh.2012.07.008
• Lyme disease.  
  Kay J, Preibisz JM, Comprehensive Therapy 1993;19:157-62
• Musculoskeletal Pain, Myofascial Pain Syndrome, and the Fibromyalgia Syndrome.  
  Kay J, Arthritis Rheum 1994;37:1833-4
• Principles and Practice of Dialysis.  
  Kay J, Amyloid: Int J Exp Clin Invest 1995;2:217-20
• Dialysis-Related Amyloidosis.  
  Kay J, Amyloid: Int J Exp Clin Invest 1996;3:294-5
• Osteoarticular disorders of renal origin: disease-related and iatrogenic.  
  Kay J, Bardin T, Best Pract Res Clin Rheumatol. 2000;14:285-305
• The role of interleukin-1 in the pathogenesis of rheumatoid arthritis.  
  Kay J, Calabrese LH, Rheumatol 2004; 43(Suppl 3): 2-9
• A systematic approach to managing rheumatological conditions: Preface.  
  So AK-L, Kay J, Best Pract Res Clin Rheumatol 2006;20:623-625
• What causes nephrogenic systemic fibrosis?  
  Kay J, The Rheumatologist. 2007;1(9):1,18-20
• Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity.  
  Todd DJ, Kay J, Curr Rheumatol Reports 2008, 10:195–204
• Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.  
  Kay J, Ann Rheum Dis 2008;67(Suppl 3):iii66-iii69
• Nonsteroidal anti-inflammatory drugs.  
  Kay J, Weinblatt ME, Medical Update (Brigham and Women’s Hospital).1989; 1(9):1-5
• Does rheumatoid arthritis or biologic therapy increase cancer risk?  
  Cush JJ, Kay J, Dao KH, Drug Safety Quarterly (American College of Rheumatology)
• Vascular occlusion and cardiac conduction disturbances in a patient undergoing peritoneal dialysis.  
  Kay J, Semin Dial 1993;6:135-139
• Churg-Strauss syndrome with diffuse gastrointestinal involvement.  
  Berarducci M, Thomas C, Kay J, JCR: J Clin Rheumatol 1996;2:221-6
• The association of relapsing polychondritis and myelodysplastic syndrome.  
  Salahuddin N, Libman BS, Lunde JH, Kay J, Cooper SM, JCR: J Clin Rheumatol 2000;6:146-9
• Case 29-2002: Antiphospholipid-Antibody Syndrome [letter].  
  Steele D, Mills JA, Kay J, N Engl J Med 2003; 348: 960-961
• Case 35-2004: Nephrogenic Fibrosing Dermopathy [letter].  
  Moschella SM, Kay J, Liu V, N Engl J Med 2005; 352: 1723-1724
• Nephrogenic systemic fibrosis in patients undergoing hemodialysis: Reply [letter].  
  Kay J, Todd DJ, Arthritis Rheum 2008; 58: 910-911
• The pitfalls of a purely clinical definition of nephrogenic systemic fibrosis: Reply [letter].  
  Todd DJ, Kay J, Arthritis Rheum 2008; 58: 1552-1554
• Development of gastrointestinal ?2-microglobulin amyloidosis correlates with time on dialysis.  
  Jimenez RE, Price DA, Pinkus GS, Gunes B. Owen WF Jr, Lazarus JM, Kay J, Turner JR, Am J Surg Pathol 1998;22:729-35
• Synovial fluid eosinophilia in Lyme disease.  
  Kay J, Eichenfield AH, Athreya BH, Doughty RA, Schumacher HR, Arthritis Rheum 1988;31:1384-9
• Activation of CD4 cells by fibronectin and anti-CD3 antibody: A synergistic effect mediated by the VLA-5 fibronectin receptor complex.  
  Matsuyama T, Yamada A, Kay J, Yamada KM, Akiyama SK, Schlossman SF, Morimoto C, J Exp Med 1989;170:1133-48
• Identification and characterization of opsonic fibronectin in synovial fluids of patients with active rheumatoid arthritis.  
  Kay J, Austen KF, Czop JK, Arthritis Rheum 1991;34:687-96
• Join now to see all

Books/Book Chapters

• Clinical manifestations and diagnosis of Felty's syndrome. 
  Kay JEditors: UpToDate, Basow DS.Waltham, MA
• Essentials of Rheumatoid Arthritis: The role of IL-6 and tocilizumab. 
  Emery P, Kay JSpringer Healthcare Ltd, London
• Indications for splenectomy in Felty's syndrome. 
  Kay JEditors: UpToDate, Basow DS.Waltham, MA
• Drug therapy in Felty's syndrome. 
  Kay JEditors: UpToDate, Basow DS.Waltham, MA
• Geriatric Medicine. 
  Chapter: Paget’s disease of bone 
  Page 483 - 494Kay J, Kantrowitz FGEditors: Rowe JW, Besdine RW.Little, Brown and Company, BostonEdition 2,
• Encyclopedia of Immunology. 
  Chapter: Fibronectin 
  Page 566 - 568Kay J, Czop JKEditors: Roitt IM, Delves PJ.Academic Press, LondonEdition 2,
• Dialysis and Transplantation. 
  Chapter: Dialysis-associated amyloidosis 
  Page 237 - 252Kay JEditors: Owen WF Jr, Pereira BJG, Sayegh M.W.B. Saunders, Co, Philadelphia
• Handbook of Dialysis. 
  Chapter: Musculoskeletal and rheumatic diseases 
  Page 627 - 641Kay J, Hano JEEditors: Daugirdas J, Ing TS, Blake PG.Lippincott Williams & Wilkins, PhiladelphiaEdition 3,
• Handbook of Dialysis. 
  Chapter: Musculoskeletal and rheumatic diseases 
  Page 685 - 699Kay JEditors: Daugirdas JT, Blake PG, Ing TS.Lippincott Williams & Wilkins, PhiladelphiaEdition 4,
• Primer on the Rheumatic Diseases. 
  Chapter: Amyloidosis 
  Page 533 - 542Sarraf P, Kay JEditors: Klippel JH, Stone JH, Crofford LJ, White PH.Springer, New YorkEdition 13,
• Essentials of Physical Medicine and Rehabilitation: Musculoskeletal Disorders, Pain, and Rehabilitation. 
  Chapter: Rheumatoid arthritis of the hand 
  Page 161 - 165Ring D, Kay JEditors: Frontera WR, Silver JK, and Rizzo TD Jr.Saunders, PhiladelphiaEdition 2,
• The ACR at 75: A Diamond Jubilee. 
  Chapter: The American College of Rheumatology Annual Scientific Meeting 
  Page 53 - 56Kay JEditors: Pisetsky D.Wiley-Blackwell (John Wiley & Sons, Inc.), Hoboken, NJ
• Rheumatology. 
  Chapter: Miscellaneous Arthropathies Including Synovial Tumors and Foreign Body Synovitis and Nephrogenic Systemic Fibrosis 
  Page 1677 - 1688Kay J, Schumacher HREditors: Hocherg M, Silman A, Smolen J, Weinblatt M, Weisman M.Elsevier Health Sciences, PhiladelphiaEdition 5,
• Case Studies in Systemic Sclerosis. 
  Chapter: A 65-year old woman with hardened skin, joint contractures, and yellow scleral plaques 
  Page 85 - 94Kay JEditors: Silver RM, Denton C.Springer, New York
• Rheumatic Diseases and the Skin. 
  Chapter: Nephrogenic systemic fibrosis 
  Kay J, Nazarian RMEditors: Matucci-Cerinic M, Furst D, Fiorentino D.Springer, New York
• Harvard Medical School Family Health Guide. 
  Chapter: Bones, Joints, and Muscles 
  Kay JEditors: Komaroff AL.Simon & Schuster, New YorkEdition 2,
• Rheumatology Medical Knowledge Self-Assessment Program. 
  Kay JAmerican College of Physicians, PhiladelphiaEdition 2,
• Contrast Media in Radiology. 
  Chapter: Allergy to radiographic contrast media: Accumulated evidence for antibody-mediated human toxicity and a new animal model 
  Page 16 - 19Brasch RC, Kay J, Mark S, Nitecki DEEditors: Amiel M.Springer-Verlag, Berlin
• Join now to see all

Abstracts/Posters

• Gender differences in baseline disease characteristics, clinical efficacy, and safety in rheumatoid arthritis patients from three randomized, double-blind, placebo-con...
  Furst DE, D. Khanna D, Hsia EC, Doyle MK, Fleischmann R, Keystone E, Kay J, Xu S, Rahman MU, Ann Rheum Dis 2010;69(Suppl3):681
• Improvement and maintenance of hemoglobin levels among rheumatoid arthritis, psoriatic arthritis & ankylosing spondylitis patients with anemia of inflammation after tr...
  Furst DE, Gathany TA, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy F, Han C, Doyle MK, Ann Rheum Dis 2012;71(Suppl3):663
• Golimumab 3-year safety update: An analysis of pooled data from the long term extensions of randomized, double-blind, placebo-controlled studies in rheumatoid arthriti...
  Kay J, Fleischmann R, Keystone E, Hsia EC, Doyle MK, Hsu B, Mack M, BeutlerA, Braun J, Kavanaugh A, Ann Rheum Dis 2012;71(Suppl3):515
• Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis and contribute separately to predicting outcom...
  Kay J, Messing SP, Kremer JM, Greenberg JD, Furst DE, Arthritis Rheum 2011;63(Suppl 10):S982-S983
• Hypophosphatemia is associated with nephrogenic systemic fibrosis: A case-control study.
  Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Bazari H, Wolf M, Kay J, Arthritis Rheum 2011;63(Suppl 10):S902
• Golimumab use and sustained clinical response in patients with active rheumatoid arthritis previously treated with anti-tumor necrosis factor alpha agents.
  Smolen J, Kay J, Landewe R, Eric L. Matteson EL, Norman B. Gaylis NB, J. Wollenhaupt J, Frederick T. Murphy FT, O. Zamani O, Yiying Zhou Y, Elizabeth C. Hsia EC and Mi..., Arthritis Rheum 2011;63(Suppl 10):S880
• Golimumab 3-year safety update: An analysis of pooled data from the long term extensions of randomized, double-blind, placebo-controlled studies in rheumatoid arthriti...
  Kay J, Fleischmann R, Keystone E, Hsia EC, Doyle MK, Hsu B, Mack M, BeutlerA, Braun J, Kavanaugh A, Arthritis Rheum 2011;63(Suppl 10):S870
• Improvement & maintenance of hemoglobin levels among rheumatoid arthritis, psoriatic arthritis & ankylosing spondylitis patients with anemia of inflammation after trea...
  Furst DE, Gathany T, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Han C, Doyle MK, Arthritis Rheum 2011;63(Suppl 10):S487
• Association of serum markers with clinical response measures in rheumatoid arthritis patients treated with golimumab, a human anti-TNF alpha monoclonal antibody.
  Wagner C, Rahman M, Genovese M, E. Matteson E, Kay J, Keystone E, Hsia E, Doyle M, Elashoff M, Visvanathan S., Ann Rheum Dis 2010;69(Suppl3):532
• Key pharmacological parameters support monthly dosing for golimumab.
  Rahman MU, Cai A, Lacy E, Kay J, Keystone EC, Matteson EL, Hu C, Zhou Y, Shealy D, Arthritis Rheum 2010;62(Suppl 10):S759
• Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis patients with lymphoma.
  Baecklund E, Ekström Smedby K, Backlin C, Rönnelid J, Åhlin E, Toes R, Askling J, Hochberg E, Murali M, Klareskog L, Huizinga T, Hochberg F, Kay J, Arthritis Rheum 2010;62(Suppl 10):S422
• Preclinical efficacy of a PDGFR inhibitor, ARRY-768, in a rat model of gadolinium-induced fibrosis.
  Cox A, High W, Lee P, Allen S, Callejo M, Marmsater F, Munson M, Robinson J, Lyssikatos J, Yeh T, Kay J, Woessner R, Keystone Fibrosis Symposium, Keystone, CO
• GO-AFTER Study Investigators. Golimumab in rheumatoid arthritis patients previously treated with anti-TNF alpha agents: 2-year results from GO-AFTER study.
  Smolen JS, Kay J, Doyle M, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, Ann Rheum Dis 2010;69(Suppl3):681
• Treatment of rheumatoid arthritis (RA) with a MEK kinase inhibitor: Results of a 12-week, randomized, placebo-controlled phase 2 study in patients with active RA on a ...
  Kay J, Morales R, L. Bellatin RL, Brzezicki J, Sirály JP, Neitzel A, James A, Miller SG, Maksymowych W, Yates J, Rojas-Caro S, Weisman MH, Ann Rheum Dis 2010;69(Suppl3):54
• Pooled safety data from golimumab randomized, controlled trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
  Kay J, Smolen JS, Fleischmann RM, Keystone EC, Rahman MU, Hsia EC, Doyle MK, Hsu B, Mack M, Beutler A, van der Heijde DM, Braun J, Kavanaugh A, Ann Rheum Dis 2010;69(Suppl3):529
• Safety of golimumab, a new human anti-TNF antibody, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: An analysis of pooled data from randomize...
  Kay J, Fleischmann RM, Keystone EC, Rahman MU, Hsia EC, Doyle MK, et al, Arthritis Rheum 2009; 60 (Suppl 10):790
• Golimumab is efficacious in anti-TNF Agent experienced patients with active RA regardless of type of agent or reason for discontinuation of prior anti-TNF agent: Resul...
  Smolen JS, Doyle MK, Kay J, Matteson EL, Landewe R, Hsia EC et al, Arthritis Rheum 2009; 60 (Suppl 10):1664
• Golimumab in rheumatoid arthritis patients previously treated with anti-TNF agents (GO-AFTER Study): Week 52 Results.
  Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al, Arthritis Rheum 2009; 60(Suppl 10):1669
• Association of serum markers with clinical response measures in rheumatoid arthritis patients treated with golimumab, a human anti-TNF monoclonal antibody.
  Wagner C, Rahman MU, Genovese MC, Matteson EL, Kay J, Keystone EC, et al, Arthritis Rheum 2009; 60 (Suppl 10):1674
• Efficacy and safety of oral imatinib mesylate in patients with nephrogenic systemic fibrosis.
  Kay, J, Sullivan ME, Patel TV, Arthritis Rheum 2009; 60 (Suppl 10):458
• Golimumab significantly improves physical function & fatigue in RA patients previously treated with anti-TNFa agents: Results from the GO-AFTER study.
  Kay J, Doyle MK, Smolen J, Buchanan J, Matteson EL, Hsia EC, Landewé R, Zhou Y, Parasuraman S, Rahman MU, on behalf of the GO-LIVE Study Group, Ann Rheum Dis 2009; 68 (Suppl3):423
• Join now to see all

Lectures

• Seminar in Advanced Rheumatology and Board Review Course 
  NYU Langone Medical Center, New York, New York - 3/21/2013
• 2-Microglobulin Amyloidosis and Advanced Glycosylation Endproducts. 
  Tufts-New England Medical Center, Boston, MA, 1996, Boston Medical Center, Boston, MA, 1997
• 2-Microglobulin Amyloidosis: An Update. 
  Roger Williams General Hospital, Providence, RI, University of Massachusetts Medical Center, Worcest
• Rheumatology. 
• Amyloidosis in the Hemodialysis Patient. 
  New England Spring Meeting of Council on Renal Nutrition Burlington, MA
• Experts Speak on Arthritis: Patients and Professionals Discuss New Strategies for Managing Arthritis. 
  The Arthritis Foundation Massachusetts Chapter, Boston, MA
• Amyloidosis. 
  Roger Williams General Hospital, Providence, RI
• COX-2 Inhibition: A New Paradigm in Anti-inflammatory Drug Therapy. 
  Maine Medical Center, Portland, ME
• COX-2: What’s New? 
  University of Massachusetts Medical Center, Worcester, MA
• Rheumatoid Arthritis: New Approaches to Treatment. 
  Yale-New Haven Hospital, New Haven, CT
• New Approaches in the Treatment of Rheumatoid Arthritis. 
  Dartmouth Hitchcock Medical Center, Lebanon, NH
• Rheumatoid Arthritis: From Aspirin to Anakinra. 
  Roger Williams Hospital, Providence, RI
• Rheumatologic Complications of Chronic Renal Failure. 
  Multiple Location, 2003, 2004, 2006
• Recent Advances in the Treatment of Rheumatoid Arthritis. 
  New England Baptist Hospital, Boston, MA
• Recent Advances in the Management of Rheumatoid Arthritis. 
  St. Vincent’s Hospital, Worcester, MA
• Nephrogenic Systemic Fibrosis: An Epidemic of Gadolinium Toxicity. 
  St. Elizabeth’s Hospital, Brighton, MA, Newton-Wellesley Hospital, Newton, MA
• Gadolinium-Associated Systemic Fibrosis: An Epidemic of Contrast Agent Toxicity. 
  Tufts-New England Medical Center, Boston, MA, MetroWest Medical Center, Framingham, MA
• An Update on the Treatment of Rheumatoid Arthritis. 
  Cooley-Dickinson Hospital, Northampton, MA
• Joint Problems in End-Stage Kidney Disease. 
  Roger Williams Hospital, Providence, RI
• Nonsteroidal Anti-inflammatory Drugs. 
  Hale Hospital, Haverhill, MA
• Fibronectin in Rheumatoid Arthritis. 
  Tufts-New England Medical Center, Boston, MA, 1989, University Hospital, Boston, MA, 1991
• Hemodialysis Amyloid Arthropathy. 
  Rhode Island Hospital, Providence, RI
• Lyme Disease, Fibromyalgia, and Other Causes of Chronic Fatigue: Differential Diagnosis and Management. 
  Arthritis Foundation, Massachusetts Chapter
• Dialysis-Related Amyloidosis: A Consequence of Therapy for Renal Failure? 
  University Hospital, Boston, MA
• Arthritis Therapy: What’s New? 
  Maine Society of Orthopaedic Surgeons, Waterville Valley, ME
• Join now to see all

Other

• Nephrogenic Systemic Fibrosis. 
  Kay J, Harrison's Principles of Internal Medicine
  http://www.accessmedicine.com/updatesContent.aspx?aid=1001547
• Septic bursitis 
  Kay J, Kotton CN
  http://www.uptodate.com/contents/septic-bursitis
  UpToDate, Wolters Kluwer Health - 2012-11-20
• Clinical manifestations and diagnosis of Felty's syndrome 
  Kay J
  http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-feltys-syndrome
  UpToDate, Wolters Kluwer Health - 2012-08-23
• Drug therapy in Felty's syndrome 
  Kay J
  http://www.uptodate.com/contents/drug-therapy-in-feltys-syndrome
  UpToDate, Wolters Kluwer Health - 2012-02-25
• Indications for splenectomy in Felty's syndrome 
  Kay J
  http://www.uptodate.com/contents/indications-for-splenectomy-in-feltys-syndrome
  UpToDate, Wolters Kluwer Health - 2012-06-12
• Join now to see all